55 patents
Page 3 of 3
Utility
Benzazole compounds and methods for making and using the compounds
14 Sep 20
Disclosed are novel benzazole compounds and compositions comprising the compounds.
Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
Filed: 6 Aug 18
Utility
Antigen binding molecules to TIGIT
31 Aug 20
Provided herein are antigen binding molecules that bind to TIGIT, include antibodies and antigen binding fragments thereof.
Ramesh R. Bhatt, Todd Kinsella, Wei Li
Filed: 30 Nov 17
Utility
2,4-pyrimidinediamine compounds and their uses
13 Jul 20
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 20 Nov 19
Utility
2,4-diamino-pyrimidine compounds and method for making and using the compounds
13 Jul 20
Yan Chen, Rose Yen, Jiaxin Yu, Vanessa Taylor, Rajinder Singh
Filed: 25 Jun 17
Utility
Fused imidazole derivatives as TGF-beta inhibitors
29 Jun 20
Rajinder Singh, Todd Kinsella, Jiaxin Yu, Marina Gelman, Ihab S. Darwish
Filed: 15 Nov 15
Utility
2,4-pyrimidinediamine compounds and their uses
15 Jun 20
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 20 Jan 11
Utility
Nrf2 activating compounds and uses thereof
11 May 20
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 12 Nov 17
Utility
Kinase inhibitors and methods for making and using
16 Mar 20
Vanessa Taylor, Yan Chen, Rose Yen
Filed: 27 Jun 18
Utility
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
2 Mar 20
The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda, Thomas Sun, Valentino J. Stella
Filed: 27 Nov 18
Utility
Nrf2 activating compounds and uses thereof
10 Feb 20
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 12 Nov 17
Utility
Compositions and methods for inhibition of the JAK pathway
10 Feb 20
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Yan Chen, Vanessa Taylor, Hui Li, Rajinder Singh
Filed: 23 May 18
Utility
Fumarate analogs and uses thereof
2 Dec 19
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders.
Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
Filed: 20 Sep 17
Utility
Compositions and methods for inhibition of the JAK pathway
18 Nov 19
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
Filed: 7 Feb 18
Utility
Tetrazolones as a carboxylic acid bioisosteres
21 Oct 19
The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent.
Matthew Duncton, Rajinder Singh
Filed: 7 Jun 17
Utility
Tyrosine kinase inhibitors
7 Oct 19
Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
Filed: 3 Oct 18